Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
Metrics: PDF 574 views | HTML 548 views | ?
Christopher H. Lieu1, Peter J. Klauck1, Patrick K. Henthorn1, John J. Tentler1, Aik-Choon Tan1, Anna Spreafico1, Heather M. Selby1, Blair C. Britt1, Stacey M. Bagby1, John J. Arcaroli1, Wells A. Messersmith1, Todd M. Pitts1 and S. Gail Eckhardt1
1 Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Christopher H. Lieu, email:
Keywords: MEK, colorectal cancer, patient derived xenografts, TAK-733
Received: August 09, 2015 Accepted: September 05, 2015 Published: October 01, 2015
Background: CRC is a significant cause of cancer mortality, and new therapies are needed for patients with advanced disease. TAK-733 is a highly potent and selective investigational novel MEK allosteric site inhibitor.
Materials and Methods: In a preclinical study of TAK-733, a panel of CRC cell lines were exposed to varying concentrations of the agent for 72 hours followed by a sulforhodamine B assay. Twenty patient-derived colorectal cancer xenografts were then treated with TAK-733 in vivo. Tumor growth inhibition index (TGII) was assessed to evaluate the sensitivity of the CRC explants to TAK-733 while linear regression was utilized to investigate the predictive effects of genotype on the TGII of explants.
Results: Fifty-four CRC cell lines were exposed to TAK-733, while 42 cell lines were deemed sensitive across a broad range of mutations. Eighty-two percent of the cell lines within the sensitive subset were BRAF or KRAS/NRAS mutant, whereas 80% of the cell lines within the sensitive subset were PIK3CA WT. Twenty patient-derived human tumor CRC explants were then treated with TAK-733. In total, 15 primary human tumor explants were found to be sensitive to TAK-733 (TGII ≤ 20%), including 9 primary human tumor explants that exhibited tumor regression (TGII > 100%). Explants with a BRAF/KRAS/NRAS mutant and PIK3CA wild-type genotype demonstrated increased sensitivity to TAK-733 with a median TGII of -6%. MEK-response gene signatures also correlated with responsiveness to TAK-733 in KRAS-mutant CRC.
Conclusions: The MEK inhibitor TAK-733 demonstrated robust antitumor activity against CRC cell lines and patient-derived tumor explants. While the preclinical activity observed in this study was considerable, single-agent efficacy in the clinic has been limited in CRC, supporting the use of these models in an iterative manner to elucidate resistance mechanisms that can guide rational combination strategies.
Christopher H. Lieu
Primary Contact _
Peter J. Klauck
Patrick K. Henthorn
John J. Tentler
Heather M. Selby
Blair C. Britt
Stacey M. Bagby
John J. Arcaroli
Wells A. Messersmith
Todd M. Pitts
S. Gail Eckhardt
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.